Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells

Abstract

Aim: Despite considerable efforts to reverse clinical multidrug resistance (MDR), targeting the predominant multidrug transporter ABCB1/P-glycoprotein (P-gp) using small molecule inhibitors has been unsuccessful, possibly due to the emergence of alternative drug resistance mechanisms. However, the non-specific P-gp inhibitor cyclosporine (CsA) showed significant clinical benefits in patients with acute myeloid leukemia (AML), which likely represents the only proof-of-principle clinical trial using several generations of MDR inhibitors. Nevertheless, the mutational mechanisms that may underlie unsuccessful MDR modulation by CsA are not elucidated because of the absence of CsA-relevant cellular models. In this study, our aims were to establish CsA-resistant leukemia models and to examine the presence or absence of ABCB1 exonic mutations in these models as well as in diverse types of human cancer samples including AMLs.

Methods: Drug-resistant lines were established by stepwise drug co-selection and characterized by drug sensitivity assay, rhodamine-123 accumulation, [³H]-labeled drug export, ABCB1 cDNA sequencing, and RNase protection assay. The genomic stability of the ABCB1 coding regions was evaluated by exome sequencing analysis of variant allele frequencies in human populations. Moreover, the mutational spectrum of ABCB1 was further assessed in diverse types of cancer samples including AMLs in the Cancer Genome Atlas (TCGA) at the National Cancer Institute.

Results: We report the development of two erythroleukemia variants, RVC and RDC, which were derived by stepwise co-selection of K562/R7 drug-resistant leukemia cells with the etoposide-CsA and doxorubicin-CsA drug combinations, respectively. Interestingly, both RVC and RDC cell lines, which retained P-gp expression, showed altered multidrug-resistant phenotypes that were resistant to CsA modulation. Strikingly, no mutations were found in the ABCB1 coding regions in these variant cells even under long-term stringent drug selection. Genomically, ABCB1 displayed relatively low variant allele frequencies in human populations when compared with several ABC superfamily members. Moreover, ABCB1 also exhibited a very low mutational frequency in AMLs compared with all types of human cancer. In addition, we found that CsA played a role in undermining the selection of highly drug-resistant cells via induction of low-level and unstable drug resistance.

Conclusion: Our data indicate that ABCB1 coding regions are genomically stable and relatively resistant to drug-induced mutations. Non-ABCB1 mutational mechanisms are responsible for the drug-resistant phenotypes in both RVC and RDC cell lines, which are also prevalent in clinical AML patients. Accordingly, we propose several relevant models that account for the development of alternative drug resistance mechanisms in the absence of ABCB1 mutations.

Keywords

Cancer / leukemia / multidrug resistance / ABCB1 / P-glycoprotein / cyclosporine / mutation

References

[1] Robey RW,Hall MD.Revisiting the role of ABC transporters in multidrug-resistant cancer..Nat Rev Cancer2018;18:452-64 PMCID:PMC6622180

[2] Sikic BI,Lum BL.Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein..Cancer Chemother Pharmacol1997;40:S13-9

[3] Chen KG.Molecular pathways: regulation and therapeutic implications of multidrug resistance..Clin Cancer Res2012;18:1863-9 PMCID:PMC3359695

[4] Amiri-Kordestani L,Kurdziel K,Bates SE.Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies..Drug Resist Updat2012;15:50-61 PMCID:PMC3680361

[5] Tamaki A,Szakacs G,Bates SE.The controversial role of ABC transporters in clinical oncology..Essays Biochem2011;50:209-32 PMCID:PMC6944313

[6] Bartlett NL,Fisher GA.Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance..J Clin Oncol1994;12:835-42

[7] Lum BL,Yahanda AM.Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance..J Clin Oncol1992;10:1635-42

[8] Yahanda AM,Fisher GA.Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance..J Clin Oncol1992;10:1624-34

[9] List AF,Willman CL.Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study..Blood2001;98:3212-20

[10] List AF,Greer J.Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia..J Clin Oncol1993;11:1652-60

[11] Liu Yin JA,Rees JK,Party UMALW.Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial..Br J Haematol2001;113:713-26

[12] Advani R,Lum BL.A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance..Clin Cancer Res2001;7:1221-9

[13] Fracasso PM,Fears CL.Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies..J Clin Oncol2000;18:1124-34

[14] Dorr R,Spier C.Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia..J Clin Oncol2001;19:1589-99

[15] Advani R,Fisher GA.A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance..Ann Oncol2005;16:1968-73

[16] Lancet JE,Duran GE.A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia..Leuk Res2009;33:1055-61

[17] Cripe LD,Paietta EM.Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999..Blood2010;116:4077-85 PMCID:PMC2993615

[18] Marcelletti JF,Cripe LD.Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia..Cytometry B Clin Cytom2019;96:57-66 PMCID:PMC6340737

[19] Smith BD,Burke P.Response to ‘comparison of “sequential” versus “standard” chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial’..Br J Haematol2003;122:164-5

[20] Choi KH,Kriegler M.An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene..Cell1988;53:519-29

[21] Chen G,Steger KA.Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins..J Biol Chem1997;272:5974-82

[22] Chen KG,Duran GE,Sikic BI.Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted phe(335)..Mol Pharmacol2000;57:769-77

[23] Kimchi-Sarfaty C,Kim IW.A “silent” polymorphism in the MDR1 gene changes substrate specificity..Science2007;315:525-8

[24] Morisaki K,Ozvegy-Laczka C.Single nucleotide polymorphisms modify the transporter activity of ABCG2..Cancer Chemother Pharmacol2005;56:161-72

[25] Zu B,Wang X.MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis..Pharmacogenomics2014;15:667-77

[26] Chen KG,Schaner ME.Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line..Cancer Res2005;65:9388-97

[27] Chen KG,Fleming WH,Sikic BI.Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection..Cancer Res1994;54:4980-7

[28] Huff LM,Iglesias A,Lee JS.Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples..Cancer Res2005;65:11694-703

[29] Patch AM,Etemadmoghadam D.Whole-genome characterization of chemoresistant ovarian cancer..Nature2015;521:489-94

[30] Mickley LA,Weng Z.Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors..Blood1998;91:1749-56

[31] Calcagno AM,To KK.Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes..Br J Cancer2008;98:1515-24 PMCID:PMC2386965

[32] van der Kolk DM,Scheffer GL.Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia..Blood2002;99:3763-70

[33] Zhan Z,Gamelin E.Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay..Blood1997;89:3795-800

[34] Doyle LA,Abruzzo LV.A multidrug resistance transporter from human MCF-7 breast cancer cells..Proc Natl Acad Sci U S A1998;95:15665-70 PMCID:PMC28101

[35] Cole SP,Gerlach JH.Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line..Science1992;258:1650-4

[36] Steinbach D,Sauerbrey A.ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia..Clin Cancer Res2006;12:4357-63

[37] Wulf GG,Inagaki N.ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport..Haematologica2004;89:1395-7

[38] Dumontet C.Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death..J Clin Oncol1999;17:1061-70

[39] Giannakakou P,Fojo T.Tubulin/microtubules: still a promising target for new chemotherapeutic agents..J Natl Cancer Inst2000;92:182-3

[40] Beketic-Oreskovic L,Chen KG,Sikic BI.Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833..J Natl Cancer Inst1995;87:1593-602

[41] Dumontet C,Tsuchiya E.Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization..Bull Cancer2004;91:E81-112

[42] Jaffrezou JP,Derry WB.Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833..Oncol Res1995;7:517-27

[43] Duran GE,Francisco EB.Mechanisms of resistance to cabazitaxel..Mol Cancer Ther2015;14:193-201 PMCID:PMC4447706

[44] Harker WG.Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA..Cancer Res1985;45:4091-6

[45] Harker WG,Sikic BI.Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs..Cancer Res1983;43:4943-50

[46] Zhang JT,Xie C.Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer..Biochim Biophys Acta2013;1833:2961-9

[47] Xie C,Zhang JT.CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer..Oncogene2013;32:2282-9191e1-7

[48] Kajiji S,Grizzuti K.Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site..Biochemistry1993;32:4185-94

[49] Qadir M,Fricke SM.Cyclosporin A is a broad-spectrum multidrug resistance modulator..Clin Cancer Res2005;11:2320-6

[50] Sato M,Fukunaga M.Cyclosporine A induces apoptosis of human lung adenocarcinoma cells via caspase-dependent pathway..Anticancer Res2011;31:2129-34

[51] Dekkers JF,Kruisselbrink E.Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis..Sci Transl Med2016;8:344ra84

[52] Chen KG,Zheng W.Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids..Drug Discov Today2019; PMCID:PMC6856431

[53] Sachs N.Organoid cultures for the analysis of cancer phenotypes..Curr Opin Genet Dev2014;24:68-73

[54] Chen KG,Park K.Pluripotent stem cell platforms for drug discovery..Trends Mol Med2018;24:805-20 PMCID:PMC6117164